JP6378630B2 - 皮膚の疾患、障害、および異常の治療のための肝臓ｘ受容体（ｌｘｒ）調節因子 - Google Patents

皮膚の疾患、障害、および異常の治療のための肝臓ｘ受容体（ｌｘｒ）調節因子 Download PDF

Info

Publication number
JP6378630B2
JP6378630B2 JP2014560060A JP2014560060A JP6378630B2 JP 6378630 B2 JP6378630 B2 JP 6378630B2 JP 2014560060 A JP2014560060 A JP 2014560060A JP 2014560060 A JP2014560060 A JP 2014560060A JP 6378630 B2 JP6378630 B2 JP 6378630B2
Authority
JP
Japan
Prior art keywords
group
carbon atoms
further embodiment
alkyl
alkyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014560060A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015512883A (ja
JP2015512883A5 (enExample
Inventor
ラジュ モーハン，
ラジュ モーハン，
Original Assignee
ラレキサー セラピューティクス，インク
ラレキサー セラピューティクス，インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラレキサー セラピューティクス，インク, ラレキサー セラピューティクス，インク filed Critical ラレキサー セラピューティクス，インク
Publication of JP2015512883A publication Critical patent/JP2015512883A/ja
Publication of JP2015512883A5 publication Critical patent/JP2015512883A5/ja
Application granted granted Critical
Publication of JP6378630B2 publication Critical patent/JP6378630B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2014560060A 2012-03-02 2013-02-28 皮膚の疾患、障害、および異常の治療のための肝臓ｘ受容体（ｌｘｒ）調節因子 Expired - Fee Related JP6378630B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261606160P 2012-03-02 2012-03-02
US61/606,160 2012-03-02
PCT/US2013/028438 WO2013130892A1 (en) 2012-03-02 2013-02-28 Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018145589A Division JP6800922B2 (ja) 2012-03-02 2018-08-02 皮膚の疾患、障害、および異常の治療のための肝臓ｘ受容体（ｌｘｒ）調節因子

Publications (3)

Publication Number Publication Date
JP2015512883A JP2015512883A (ja) 2015-04-30
JP2015512883A5 JP2015512883A5 (enExample) 2016-04-28
JP6378630B2 true JP6378630B2 (ja) 2018-08-22

Family

ID=49083313

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014560060A Expired - Fee Related JP6378630B2 (ja) 2012-03-02 2013-02-28 皮膚の疾患、障害、および異常の治療のための肝臓ｘ受容体（ｌｘｒ）調節因子
JP2018145589A Expired - Fee Related JP6800922B2 (ja) 2012-03-02 2018-08-02 皮膚の疾患、障害、および異常の治療のための肝臓ｘ受容体（ｌｘｒ）調節因子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018145589A Expired - Fee Related JP6800922B2 (ja) 2012-03-02 2018-08-02 皮膚の疾患、障害、および異常の治療のための肝臓ｘ受容体（ｌｘｒ）調節因子

Country Status (25)

Country Link
US (5) US8987318B2 (enExample)
EP (2) EP2820013B9 (enExample)
JP (2) JP6378630B2 (enExample)
KR (1) KR102112879B1 (enExample)
CN (1) CN104284893B (enExample)
AU (1) AU2013225840B2 (enExample)
BR (1) BR112014021515A2 (enExample)
CA (1) CA2866113C (enExample)
CY (1) CY1120742T1 (enExample)
DK (1) DK2820013T3 (enExample)
ES (1) ES2691079T3 (enExample)
HR (1) HRP20181623T1 (enExample)
HU (1) HUE040231T2 (enExample)
IL (1) IL234413B (enExample)
LT (1) LT2820013T (enExample)
MX (1) MX361349B (enExample)
NZ (1) NZ629636A (enExample)
PL (1) PL2820013T3 (enExample)
PT (1) PT2820013T (enExample)
RS (1) RS57863B9 (enExample)
SG (2) SG11201405378VA (enExample)
SI (1) SI2820013T1 (enExample)
SM (1) SMT201800630T1 (enExample)
TR (1) TR201815013T4 (enExample)
WO (1) WO2013130892A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2820013T3 (pl) 2012-03-02 2019-01-31 Ralexar Therapeutics, Inc. Modulatory receptorów X wątroby (LXR) do leczenia chorób, zaburzeń i stanów skórnych
ES2694001T3 (es) * 2013-03-15 2018-12-17 Bristol-Myers Squibb Company Moduladores de LXR
CN104151300B (zh) * 2013-05-15 2018-07-13 中国医学科学院医药生物技术研究所 一组2,3-二取代的苯并喹唑啉类的肝x受体的激动剂及用途
MX2016002930A (es) * 2013-09-04 2016-12-02 Ralexar Therapeutics Inc Moduladores del receptor x hepatico (lxr).
SI3041835T1 (sl) * 2013-09-04 2020-09-30 Ellora Therapeutics, Inc. Modulatorji jetrnih X receptorjev (LXR)
US10669296B2 (en) 2014-01-10 2020-06-02 Rgenix, Inc. LXR agonists and uses thereof
WO2017115319A2 (en) 2015-12-30 2017-07-06 Consejo Nacional De Investigaciones Científicas Y Técnicas (Conicet) Use of brassinosteroid analogs for the treatment of dermal disorders by selectively modulating liver x receptors (lxr) and dermal disease treatment by brassinosteroid analogs acting as selective liver x receptor (lxr) modulators
CA3010883A1 (en) 2016-01-11 2017-07-20 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
AU2018373028A1 (en) 2017-11-21 2020-04-30 Inspirna, Inc. Polymorphs and uses thereof
CN114126618A (zh) 2019-07-15 2022-03-01 诺华股份有限公司 用肝脏x受体激动剂治疗睑板腺功能障碍的方法
EP4073025B1 (en) 2019-12-13 2024-03-27 Inspirna, Inc. Metal salts and uses thereof
WO2022249006A1 (en) * 2021-05-24 2022-12-01 Novartis Ag Use of 1,2,4-oxadiazole derivatives as liver x receptor agonists

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1199771A (en) * 1915-07-01 1916-10-03 Bates Valve Bag Co Wire-twisting machine.
WO2002024632A2 (en) 2000-09-18 2002-03-28 Glaxo Group Limited Substituted aminopropoxyaryl derivatives useful as agonists for lxr
AUPR738301A0 (en) 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
MXPA04011690A (es) 2002-05-24 2005-03-31 Pharmacia Corp Moduladores de receptor x de higado de sulfona.
US6900244B2 (en) 2002-05-24 2005-05-31 Pharmacia Corporation Anilino liver X-receptor modulators
ES2361924T3 (es) 2002-12-20 2011-06-24 X-Ceptor Therapeutics, Inc. Derivados de isoquinolinona y su uso como agentes terapéuticos.
JP2006193426A (ja) 2003-09-05 2006-07-27 Sankyo Co Ltd 置換された縮環ピリミジン−４（３ｈ）−オン化合物
WO2005113499A1 (ja) 2004-05-20 2005-12-01 Sankyo Company, Limited インドール化合物
TW200606133A (en) 2004-06-30 2006-02-16 Sankyo Co Substituted benzene compounds
BRPI0514017A (pt) 2004-08-03 2008-05-27 Wyeth Corp indazóis úteis no tratamento de doenças cardiovasculares
US20070060589A1 (en) * 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases
WO2006109633A1 (ja) 2005-04-07 2006-10-19 Daiichi Sankyo Company, Limited 置換インドール化合物
US7213797B2 (en) 2005-05-20 2007-05-08 Garland Jerome Gaskins Deck board straightener
CA2613517A1 (en) * 2005-06-27 2007-01-04 Exelixis, Inc. Pyrazole based lxr modulators
CN101248049B (zh) * 2005-06-27 2013-08-28 埃克塞利希斯专利有限责任公司 咪唑类lxr调节剂
PT1940786E (pt) 2005-09-16 2010-10-04 Arrow Therapeutics Ltd Derivados de bifenilo e sua utilização no tratamento de hepatite c
WO2007034279A2 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. C3a antagonists and pharmaceutical compositions thereof
AU2006337682A1 (en) 2005-11-14 2007-08-16 Irm Llc Compounds and compositions as LXR modulators
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
TW200825054A (en) 2006-10-18 2008-06-16 Wyeth Corp Quinoline compounds
AU2007333194A1 (en) 2006-12-08 2008-06-19 Exelixis, Inc. LXR and FXR modulators
EP2137158A4 (en) * 2007-02-28 2012-04-18 Methylgene Inc LOW-MOLECULAR INHIBITORS OF PROTEINARGININE METHYLTRANSFERASES (PRMTS)
CN101679311A (zh) 2007-05-18 2010-03-24 惠氏公司 喹唑啉化合物
WO2009011850A2 (en) * 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
RU2454412C2 (ru) 2007-08-13 2012-06-27 Ф.Хоффманн-Ля Рош Аг Новые пиперазинамидные производные
CN101945871A (zh) 2007-12-21 2011-01-12 惠氏有限责任公司 咪唑并[1，2-a]吡啶化合物
BRPI0821315A2 (pt) 2007-12-21 2019-09-24 Wyeth Llc compostos benzimidazol
JP2011520884A (ja) * 2008-05-13 2011-07-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を変調するスルホン化合物
US8063088B2 (en) 2008-06-11 2011-11-22 Hoffmann-La Roche Inc. Imidazolidine derivatives
JP2012508250A (ja) 2008-11-07 2012-04-05 ワイス・エルエルシー キノキサリン系のｌｘｒモジュレーター
EP2367801A1 (en) 2008-11-19 2011-09-28 Wyeth LLC Polar quinazolines as liver x receptors ( lxrs ) modulators
AU2009330233A1 (en) 2008-12-22 2011-07-07 Merck Sharp & Dohme Corp. Gamma secretase modulators
US20120058133A1 (en) * 2009-02-19 2012-03-08 President And Fellows Of Harvard College Inhibition of trna synthetases and therapeutic applications thereof
EP2398474A4 (en) 2009-02-23 2012-12-05 Presidio Pharmaceuticals Inc HCV NS5A SHEMMER
AU2010254082B2 (en) 2009-05-28 2015-01-29 Exelixis, Inc. LXR modulators
GB0919757D0 (en) 2009-11-12 2009-12-30 Johnson Matthey Plc Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
US20120263646A1 (en) 2009-10-15 2012-10-18 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
US8906943B2 (en) 2010-08-05 2014-12-09 John R. Cashman Synthetic compounds and methods to decrease nicotine self-administration
EP2604602A4 (en) * 2010-08-11 2013-12-18 Taisho Pharmaceutical Co Ltd HETEROARYL PYRAZOLE DERIVATIVE
CA2809830C (en) * 2010-08-27 2019-09-10 Calcimedica, Inc. Compounds comprising n-acyl-2-amino-1,3-thiazole for modulating intracellular calcium
AR088728A1 (es) 2011-03-25 2014-07-02 Bristol Myers Squibb Co Moduladores de lxr como prodroga de imidazol
PL2820013T3 (pl) 2012-03-02 2019-01-31 Ralexar Therapeutics, Inc. Modulatory receptorów X wątroby (LXR) do leczenia chorób, zaburzeń i stanów skórnych
EP4218935A1 (en) 2012-08-13 2023-08-02 The Rockefeller University Lxrbeta agonist for the treatment of cancer
MX2016002930A (es) 2013-09-04 2016-12-02 Ralexar Therapeutics Inc Moduladores del receptor x hepatico (lxr).
SI3041835T1 (sl) 2013-09-04 2020-09-30 Ellora Therapeutics, Inc. Modulatorji jetrnih X receptorjev (LXR)

Also Published As

Publication number Publication date
NZ629636A (en) 2017-02-24
SI2820013T1 (sl) 2018-11-30
ES2691079T9 (es) 2019-02-08
TR201815013T4 (tr) 2018-11-21
CN104284893B (zh) 2017-04-19
SMT201800630T1 (it) 2019-01-11
US20150152094A1 (en) 2015-06-04
ES2691079T3 (es) 2018-11-23
JP2015512883A (ja) 2015-04-30
BR112014021515A2 (pt) 2018-03-13
US20170334897A1 (en) 2017-11-23
US9637481B2 (en) 2017-05-02
US8987318B2 (en) 2015-03-24
CA2866113C (en) 2020-05-12
HRP20181623T1 (hr) 2018-12-14
AU2013225840B2 (en) 2017-11-23
SG10201607345YA (en) 2016-11-29
HK1206030A1 (en) 2015-12-31
LT2820013T (lt) 2018-10-25
MX361349B (es) 2018-12-04
IL234413B (en) 2018-05-31
RS57863B1 (sr) 2018-12-31
JP2018184467A (ja) 2018-11-22
JP6800922B2 (ja) 2020-12-16
CA2866113A1 (en) 2013-09-06
US20180370959A1 (en) 2018-12-27
PL2820013T3 (pl) 2019-01-31
WO2013130892A1 (en) 2013-09-06
EP2820013B1 (en) 2018-07-11
PT2820013T (pt) 2018-10-25
HUE040231T2 (hu) 2019-02-28
KR102112879B1 (ko) 2020-05-19
AU2013225840A1 (en) 2014-09-18
EP2820013A1 (en) 2015-01-07
EP3441390A1 (en) 2019-02-13
KR20140146089A (ko) 2014-12-24
CY1120742T1 (el) 2019-12-11
DK2820013T3 (en) 2018-10-29
EP2820013B9 (en) 2019-01-09
MX2014010537A (es) 2015-03-09
US20210101895A1 (en) 2021-04-08
EP2820013A4 (en) 2015-11-11
SG11201405378VA (en) 2014-09-26
US20150045399A1 (en) 2015-02-12
CN104284893A (zh) 2015-01-14
RS57863B9 (sr) 2019-10-31

Similar Documents

Publication Publication Date Title
JP6378630B2 (ja) 皮膚の疾患、障害、および異常の治療のための肝臓ｘ受容体（ｌｘｒ）調節因子
US9981913B2 (en) Liver X receptor (LXR) modulators
JP6821737B2 (ja) 肝臓ｘ受容体（ｌｘｒ）のモジュレーター
US20180185325A1 (en) 12H-BENZO[b]XANTHEN-12-ONES, COMPOSITIONS CONTAINING, AND USES OF, SAME
HK1206030B (en) Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions
US9408793B2 (en) Selective compounds inhibiting CYP26A1 useful in cosmetic and pharmaceutical compositions
HK1226729A1 (en) Liver x receptor (lxr) modulators

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20150930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160309

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160804

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160816

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170314

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170614

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180606

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180710

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180727

R150 Certificate of patent or registration of utility model

Ref document number: 6378630

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees